These are top 10 stocks traded on the Robinhood UK platform in July
RA’ANANA, Israel - Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN), currently valued at $20.85 million in market capitalization, has secured a binding $22.5 million purchase order for its FDA-cleared ART100 system, the company announced Wednesday. According to InvestingPro data, this order value exceeds the company’s entire market value, though analysts maintain a $2.00 price target for the stock.
The order was placed by a privately held company based outside the United States with established commercial ties to government entities and institutional healthcare customers. According to the terms, full payment is scheduled to be made during 2025. While the company’s overall financial health score is rated as FAIR by InvestingPro, current data shows the company is quickly burning through cash, with negative free cash flow of $9.54 million in the last twelve months.
The companies have begun onboarding, logistics planning, and deployment scheduling for immediate implementation, Inspira said in a press release statement.
"We view this order as a signal of the broad activation of Inspira’s commercial model," said Dagi Ben-Noon, CEO of Inspira Technologies. "It is a vote of confidence in our technology, confirms market demand, and signals to the market that we are executing in real-world settings."
The ART100 system is approved for cardiopulmonary bypass in the U.S. and for ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S.
Inspira stated it is currently in advanced negotiations with additional healthcare companies and governmental institutions across multiple regions, with discussions progressing toward commercial agreements expected to be announced soon.
The company, which specializes in respiratory support and blood monitoring solutions, is scaling its commercial infrastructure to support global deployments. This announcement follows the company’s recent milestones including clinical integration in hospitals and manufacturing expansion. Want deeper insights into Inspira Technologies’ financial health and growth prospects? InvestingPro subscribers get access to over 30 additional financial metrics and exclusive ProTips.
In other recent news, Inspira Technologies OXY B.H.N. Ltd. has reported its initial revenue from the delivery and installation of its FDA-cleared INSPIRA ART100 life support systems at a prominent U.S. academic medical center. This marks a significant milestone for the company as it establishes its presence in the U.S. medical market, with revenue reaching the low hundreds of thousands of dollars. The ART100 system, used in cardiopulmonary bypass procedures, is also set for clinical validation in organ transplant procedures at a major Israeli medical center. This validation aims to explore the system’s capability to enhance organ viability during transplants. Additionally, Inspira Technologies is ramping up production of the ART100 system in anticipation of demand from a European governmental authority. The company is also advancing its commercialization strategy, with plans to begin deliveries in 2025, pending regulatory approval. Furthermore, Inspira Technologies announced a restructuring of its executive team, with Co-Founder and President Joe Hayon stepping down from his operational role but remaining on the Board of Directors. This executive shift is part of Inspira’s broader internal realignment to enhance its market positioning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.